Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
Currently, a combination therapy of pegylated (PEG) interferon (IFN) alpha-2b and ribavirin are being widely used for the treatment of chronic hepatitis C (CHC). We describe here a case of dual onset of type 1 DM accompanied by ketoacidosis, and Graves' disease during the combination therapy via the autoimmune process.
Hayashi
Masayuki
M
Department of Endocrinology and Metabolism, Chukyo Hospital, Nagoya 457-8510, Japan. masayuki_hayashi@chukyo-hosp.jp
Kataoka
Yuko
Y
Tachikawa
Kazushige
K
Koguchi
Hiroki
H
Tanaka
Hiroshi
H
D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000139:chemically induced; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced* / Q000150:complications; D005260:Female; D006111:Graves Disease / Q000139:chemically induced* / Q000150:complications; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D015395:Histocompatibility Antigens Class I / Q000235:genetics; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use
D000998:Antiviral Agents; D015395:Histocompatibility Antigens Class I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b